octocenter-logo

Pathophysiology of Hepatitis C

Pathophysiology of Hepatitis C

Introduction

Overview of Hepatitis C

Hepatitis C is a viral infection chiefly impacting the liver. The causative agent is the hepatitis C virus (HCV), renowned for its wide genetic diversity. The virus implements unique strategies to invade host cells, thereby initiating infection and subsequent replication. When confronted with HCV, the immune system triggers an array of innate and adaptive responses, but the virus cleverly bypasses these defence mechanisms to avoid its own demise. Chronic hepatitis C is hallmarked by hepatic inflammation and fibrosis, which over time, can escalate to life-threatening conditions such as cirrhosis and hepatocellular carcinoma. Moreover, HCV is known to induce maladies beyond the liver, thereby indicating its extrahepatic manifestations. Gaining insights into the pathophysiology of Hepatitis C is a prerequisite for innovating effective diagnostic, therapeutic, and preventive strategies to combat the disease.

Transmission of Hepatitis C

Hepatitis C predominantly disseminates through contact with HCV-infected blood. Routes of transmission include, but are not limited to, using shared or unsterilized drug-injecting equipment, acquiring an organ transplant or blood transfusion from a carrier, or coming into contact with contaminated blood in healthcare environments. There's also the possibility of vertical transmission - from an infected mother to her baby during childbirth. Sexual transmission is not as frequent, but it does occur, particularly in people who engage in high-risk behaviours such as unprotected anal intercourse or having numerous sexual partners. Contrary to common belief, Hepatitis C does not spread through casual social interactions like hugs, kisses, or shared cutlery. Knowledge of these transmission modes is vital for devising effective preventive measures and curbing the proliferation of Hepatitis C.

Hepatitis C Virus (HCV)

Structure and Replication of HCV

The structure and replication of the Hepatitis C virus (HCV) - a virus predominantly affecting liver cells - is key to discovering antiviral therapies that can target specific steps in the virus's lifecycle. The structure itself consists of a lipid sac surrounding an array of viral proteins, such as the E1 and E2 envelope glycoproteins. The replication process occurs in a series of steps starting from viral RNA translation and ending with the assembly of new viral particles. Replication units form on intracellular membranes to synthesize the new passenger viral RNA, which further develops into more viral particles.

Genotypes and Variability of HCV

Understanding the genotypes and variability of HCV and their contribution to the disease process is fundamental to the effective management and treatment of Hepatitis C. Six identified genotypes of HCV exist, each branching out into multiple subtypes. These genotypes display different geographic distributions and responses to treatment in addition to varied progression rates to chronic infection, liver cirrhosis, and hepatocellular carcinoma. Genotype 1 stands out as the most common and the least receptive to treatment, whereas genotypes 2 and 3 demonstrate higher response rates. Genotype 4 is concentrated in the Middle East and Africa, while genotypes 5 and 6 are less common and mainly occur in South Africa and Asia. The fast-paced evolution and mutation of HCV---resulting in drug-resistant strains---are challenges to the development of an effective vaccine.

Mechanisms of HCV Entry into Host Cells

Hepatitis C, a condition instigated by the Hepatitis C Virus (HCV), finds its way into host cells through a range of mechanisms. One such method includes the connectivity between the viral envelope glycoprotein E2 and specific host receptors like CD81 and SR-B1, which instigate a chain of events allowing virus's entry into the cell. In another mechanism, the viral and host cell membranes fuse, assisted by the HCV envelope glycoprotein E1 in a pH-dependent process. Additionally, HCV may enter host cells through clathrin-mediated endocytosis, a process wherein the virus is internalized through the creation of clathrin-coated vesicles. Comprehending these underlying tactics for viral entry is key to creating targeted treatments that obstruct viral entry and thereby prevent infection.

Immune Response to HCV

Innate Immune Response

The adaptive immune response to Hepatitis C (HCV) involves a number of crucial cellular components and molecules that work together to identify and eradicate the virus. Cells that present antigens, such as dendritic cells, latch on to viral antigens to present them to T cells, thus activating CD4+ helper T cells as well as CD8+ cytotoxic T cells. CD4+ T cells assist in the coordination of the immune response by releasing cytokines and aiding B cell antibody generation efforts. CD8+ T cells, however, directly aim to destroy HCV-infected cells by releasing cytotoxic molecules. Antibodies that can neutralize the virus are produced by B cells. They bind to and block viral particles, and are essential for viral clearance and can also help prevent reinfection. Thus, the adaptive immune response to HCV is a complex blend of various immune cells and molecules working collaboratively to manage and eliminate the virus.

pathophysiology of hepatitis_c

Adaptive Immune Response

Hepatitis C Virus (HCV) has managed to establish an array of evasion schemes to manipulate the immune system and establish persistent infection. One such method is the regular mutation of its surface proteins, thus rendering it a challenge for the immune system to identify and target. HCV also interferes with the creation and function of vital antiviral defenders, interferons. Furthermore, the virus can manipulate the adaptive immune response by impairing the development and function of dendritic cells and T cells. Yet another evasive strategy is the inhibition of apoptotic pathways, enabling infected liver cells to survive and propagate the virus. By circumventing the immune response, HCV can linger in the liver for extended periods, contributing to chronic inflammation and the development of liver fibrosis, cirrhosis, and hepatocellular carcinoma.

Evasion Strategies of HCV

HCV has engineered various evasive tactics that allow it to manipulate the immune system and instigate a persistent infection. This involves persistently mutating its surface proteins, making it challenging for the immune system to identify and eliminate the virus. Furthermore, HCV disrupts the interferons' role and production, a crucial component of antiviral defense. The virus can also temper the adaptive immune response by preventing maturation and hindering the function of dendritic and T cells. Another evasive action includes the suppression of apoptotic pathways, lets infected liver cells live and replicate the virus. By dodging the immune response, HCV can maintain its presence in the liver for myriad years which may lead to chronic inflammation and the formation of liver fibrosis, cirrhosis, and hepatocellular carcinoma.

Pathogenesis of Hepatitis C

Liver Inflammation and Fibrosis

Critical in the pathophysiology of Hepatitis C are liver inflammation and fibrosis. In reaction to an HCV infection, the liver undergoes an immune response initiation and liver cell annihilation called inflammation**. This inflammation instigates the liberation of cytokine, chemokine, and other inflammatory signals escalating the cycle.** Chronic inflammation encourages the gathering of extracellular matrix proteins, culminating in the formation of fibrosis and internal liver scar tissue. This scarred response is an emblem of chronic liver illnesses and if left without medical intervention, may advance to cirrhosis and hepatocellular carcinoma. The discernment of the mechanisms empowering liver inflammation, fibrosis is critical in the generation of effective treatments that will prevent disease escalation and enhance patient welfare.

Cirrhosis and Hepatocellular Carcinoma

Cirrhosis and hepatocellular carcinoma are key complications that may stem from chronic hepatitis C infection. The buildup of scar tissue and progressive fibrosis in the liver leads to the onset of cirrhosis, which results in an impaired liver function. This impairment may manifest in symptoms such as jaundice, ascites and hepatic encephalopathy. Moreover, cirrhosis enhances the risk of hepatocellular carcinoma, a type of liver cancer. The occurrence of hepatocellular carcinoma in hepatitis C patients is typically due to a confluence of direct viral effects and persistent inflammation. Constant monitoring and evaluation for these complications is pivotal in managing patients with chronic hepatitis C. Interventions like antivirus therapy and liver transplants may be deliberated to effectively prevent or manage these complications.

Extrahepatic Manifestations of HCV

Extrahepatic manifestations of HCV denote health complications caused by the Hepatitis C virus impacting parts of the body beyond the liver - like the skin, kidneys, and nervous system. Manifestations such as mixed cryoglobulinemia, which instigates blood vessel inflammation leading to skin rashes and joint pain, renal disease resulting in kidney dysfunction, and neurological disorders including peripheral neuropathy, cognitive impairments, and stroke can be observed in individuals with HCV. The mechanisms behind these manifestations continue to be the subject of research, but they are believed to be associated with the immune response elicited by the presence of the virus. Understanding and managing these extrahepatic manifestations is vital in offering comprehensive care to individuals affected by Hepatitis C.

Bibliography

  1. Martinez, M. A. & Franco, S. (2020). Therapy implications of hepatitis C virus genetic diversity. Viruses. (https://www.mdpi.com/1999-4915/13/1/41/pdf)

  2. Lapa, D., Garbuglia, A. R., Capobianchi, M. R., & Del Porto, P. (2019). Hepatitis C virus genetic variability, human immune response, and genome polymorphisms: Which is the interplay?. Cells. (https://www.mdpi.com/2073-4409/8/4/305/pdf)

  3. Ansari, M. A., Aranday-Cortes, E., Ip, C. L., da Silva Filipe, A., Lau, S. H., Bamford, C., ... & Pedergnana, V. (2019). Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. Elife, 8, e42463. (https://elifesciences.org/articles/42463.pdf)

  4. Janiak, M., Perlejewski, K., Grabarczyk, P., Kubicka-Russel, D., Zagordi, O., Berak, H., ... & Caraballo Cortés, K. (2019). Hepatitis C virus (HCV) genotype 1b displays higher genetic variability of hypervariable region 1 (HVR1) than genotype 3. Scientific Reports, 9(1), 12846. (https://www.nature.com/articles/s41598-019-49258-y)

  5. Fomiatti, R., Lenton, E., Latham, J. R., Fraser, S., Moore, D., Seear, K., & Aitken, C. (2020). Maintaining the healthy body: Blood management and hepatitis C prevention among men who inject performance and image-enhancing drugs. International Journal of Drug Policy, 75, 102592. (https://opal.latrobe.edu.au/articles/journal_contribution/Maintaining_the_healthy_body_Blood_management_and_hepatitis_C_prevention_among_men_who_inject_performance_and_image-enhancing_drugs/14050421/2/files/28983852.pdf)

  6. Tabata, K., Neufeldt, C. J., & Bartenschlager, R. (2020). Hepatitis C virus replication. Cold Spring Harbor perspectives in medicine, 10(3). (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050578/)

  7. Li, H. C., Yang, C. H., & Lo, S. Y. (2021). Hepatitis C viral replication complex. Viruses. (https://www.mdpi.com/1999-4915/13/3/520/pdf)

  8. Niepmann, M. & Gerresheim, G. K. (2020). Hepatitis C virus translation regulation. International journal of molecular sciences. (https://www.mdpi.com/1422-0067/21/7/2328/pdf)

  9. Hedskog, C., Parhy, B., Chang, S., Zeuzem, S., Moreno, C., Shafran, S. D., ... & Svarovskaia, E. S. (2019, March). Identification of 19 novel hepatitis C virus subtypes---further expanding HCV classification. In Open forum infectious diseases (Vol. 6, No. 3, p. ofz076). US: Oxford University Press. (https://academic.oup.com/ofid/article/6/3/ofz076/5362553)

  10. Irekeola, A. A., Malek, N. A., Wada, Y., Mustaffa, N., Muhamad, N. I., & Shueb, R. H. (2021). Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. Plos one, 16(5), e0251673. (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251673)

  11. Gerold, G., Moeller, R., & Pietschmann, T. (2020). Hepatitis C virus entry: Protein interactions and fusion determinants governing productive hepatocyte invasion. Cold Spring Harbor Perspectives in Medicine, 10(2). (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996445/)

  12. Sidorkiewicz, M. (2021). Hepatitis C virus uses host lipids to its own advantage. Metabolites. (https://www.mdpi.com/2218-1989/11/5/273/pdf)

  13. Leroy, H., Han, M., Woottum, M., Bracq, L., Bouchet, J., Xie, M., & Benichou, S. (2020). Virus-mediated cell-cell fusion. International Journal of Molecular Sciences, 21(24), 9644. (https://www.mdpi.com/1422-0067/21/24/9644/pdf)